A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
CompletedNCT01493557
Boehringer IngelheimAtrial Fibrillation
Start: 2011-12-31End: 2014-07-31Updated: 2015-10-05